In a nine-culture soft-tissue sarcoma panel, PRI-724 reduced viability below 50% of vehicle in seven cultures after 48 h over a 0.1–50 µM test range. SW684 and ICP020 did not reach 50% inhibition. The response was model-dependent and should not be interpreted as a universal potency value. [1]
Variable PRI-724 sensitivity across soft-tissue sarcoma cultures
Cell-based study · Nine human soft-tissue sarcoma cell lines/primary cultures: 93T449, AW, HT-1080, CP0024, SW982, SW872, SK-UT-1, SW684 and ICP020. [1]
PRI-724 reduced colorimetric viability with heterogeneous sensitivity. Seven of nine cultures fell below 50% of vehicle viability after 48 h; SW684 and ICP020 did not reach 50% inhibition over the tested range.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.1–50 µM
- Exposure duration
- 48 h
- Method
- Exposure followed by CellTiter 96 AQueous One Solution viability readout at 490 nm, normalized to vehicle-treated cultures.
- Vehicle
- DMSO vehicle control; final percentage not specified in the read main-text methods.
- Reported limits
- Individual IC50 values in Table S1 were not acquired. The paper labels the method MTT while naming CellTiter 96 AQueous One Solution; the reagent name is preserved here.
Methods and source locations
Compound reported in the paper: PRI-724; Compound label in the paper: PRI-724
Applies to the paper’s named PRI-724 material and specified model. No Adooq lot validation, salt conversion or independent stereochemical equivalence is claimed.
Results 2.1; Figure 1b and caption; Methods 4.1–4.2 and 4.11
Cultures with viability below 50% of vehicle at 48 h: Colorimetric viability; Figure 1b reports mean ± SEM from three independent experiments performed in triplicate. — Results 2.1; Figure 1b and caption; Methods 4.1–4.2
Transcriptional response with persistent nuclear β-catenin
Cell-based study · TCF reporter: HT-1080, 93T449 and AW cells; fractionation: these cells plus CP0024 and SK-UT-1. [1]
PRI-724 lowered TCF/β-catenin reporter activity, most clearly in AW cells, while nuclear β-catenin was not reduced by the fractionation/localization assessment. These experiments support a functional pathway effect; they do not measure binding affinity or independently establish target selectivity.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 µM
- Exposure duration
- Reporter: Results 2.3 describes 24 h treatment; Figure 2a caption describes treatment and transfection followed by another 24 h. Exact sequencing is not resolved. Fractionation/localization: 48 h.
- Method
- TOP/FOPFLASH reporter system with firefly/Renilla normalization; nuclear/cytoplasmic immunoblotting and immunofluorescence.
- Vehicle
- DMSO-treated controls; final percentage not specified in the read main-text methods.
- Reported limits
- Reporter timing differs between narrative/methods and caption; no precise total exposure is inferred. Supplementary Figures S3/S4 were not acquired; no numerical claim from them is adopted.
Methods and source locations
Compound reported in the paper: PRI-724; Compound label in the paper: PRI-724
Applies to the paper’s named PRI-724 material and specified model. No Adooq lot validation, salt conversion or independent stereochemical equivalence is claimed.
Results 2.3; Figure 2a–c and caption; Methods 4.1, 4.6–4.7, 4.9 and 4.11
TCF/β-catenin reporter activity relative to vehicle: Dual luciferase, firefly normalized to Renilla; Figure 2a mean ± SEM of two independent experiments in triplicate. — Results 2.3; Figure 2a and caption; Methods 4.9
Nuclear β-catenin abundance/localization: Fractionation immunoblot with α-tubulin and PARP as cytoplasmic/nuclear markers; at least three independent experiments; immunofluorescence provides supporting localization images. — Results 2.3; Figure 2b–c and caption; Methods 4.6–4.7